• Biotech’s Secret to Surviving Economic Challenges? It’s All in the Data & AI

    Sep 06 | Bio-IT World | Data has always been crucial in the life sciences industry, but in today's fiercely competitive landscape, its significance has skyrocketed. Amidst dwindling funding and mounting market pressures, biopharmaceutical companies need to better harness the power of information to design and accelerate clinical trials and timelines. More

  • Amgen’s AI Futures: Digital Twins, Unstructured Data, Human Review

    Sep 03 | Bio-IT World | Jerry Murry, senior vice president, process and development, at Amgen, gave the plenary presentation at CHI’s Bioprocessing Summit last month. With an eighteen-year tenure at Amgen—and experience at Merck and Pfizer before that—Murry has seen nearly two decades of advances in the world of bioprocessing and manufacturing. More

  • NIH Launches Native Collective Research Effort Focused on Overdose

    Sep 03 | Bio-IT World | In August, the National Institutes of Health (NIH) has launched the Native Collective Research Effort to Enhance Wellness (N CREW) Program, an effort support Native American communities to lead public health research to address overdose, substance use, and pain, including related factors such as mental health and wellness. The planned program funding totals approximately $268 million over seven years. More

  • Follow the Money: AI-Powered Cell Therapies, Cancer Risk Assessment, More

    Aug 29 | Bio-IT World | Outpace Bio will advance multiple programmed T cell product candidates to early clinical proof-of-concept for the treatment of solid tumors; Foresight Diagnostics plans to accelerate the clinical development and commercialization of their cancer recurrence testing platform, PhasED-Seq; PreciseDx plan to expand commercialization efforts for PreciseBreast risk assessment, an AI-Powered test used to assess early-stage invasive breast cancer risk; and more. More

  • Dovetail Genomics, Goenomics GmbH Partnership, Danaher Acquires Genedata, Andelyn Biosciences License Agreement With Broad Institute, More

    Aug 28 | Bio-IT World |Dovetail Genomics has formed a partnership with Goenomics GmbH to deliver an enhanced genome assembly service with the fastest turnaround time and most complete annotation available in the industry; Genedata has been acquired by Danaher; Andelyn Biosciences has entered into a License Agreement with the Broad Institute of MIT and Harvard to expand its AAV Curator Platform offering to include MyoAAV plasmids; and more. More

  • Panel Explores the Rapidly Evolving Field of Genetic Medicines

    Aug 27 | Bio-IT World | In a panel discussion at last week’s Bioprocessing Summit, four leaders in genetic medicine shared insights into the rapidly evolving world of gene editing and its potential to revolutionize the treatment of complex diseases. In a panel discussion at last week’s Bioprocessing Summit, four leaders in genetic medicine shared insights into the rapidly evolving world of gene editing and its potential to revolutionize the treatment of complex diseases. More

  • The Art of Building Techbio Teams

    Aug 23 | Bio-IT World | The biotech industry is experiencing a significant shift as technology and biology converge. This intersection, often called Techbio, is opening up new possibilities for addressing health and environmental challenges. More

  • First Clinical Trial of ‘Paradoxical Intervention’ for Cancer to Begin Soon

    Aug 21 | Bio-IT World | Cancer cells are “not like superheroes that have no vulnerabilities." Most current therapies try to block the signaling to prevent cancer’s uncontrolled division, but inevitably tumor cells resist the blockage and become far less responsive to subsequent therapy. More

  • Mice Cleared of Senescent Cells Shown to Die Healthier—Not Just Live Longer

    Aug 20 | Bio-IT World | By treating a particular brand of senescent cells, it is now possible to live healthier for longer—at least in mice. If the findings can be translated to humans, that could mean an extra decade of healthiness. Plenty of medicines are already available to help people live longer, but not necessarily with vitality. More

  • Standardized R&D Data Exchange is Here. Let’s Embrace It.

    Aug 16 | Bio-IT World | Life sciences companies have spent much time and treasure working to streamline and improve product development. The drivers have been many, but two have stood out. The first is a desire to improve efficiency and optimize cost, because it’s good for business and the pocketbooks of patients we ultimately serve. The second is to boost material traceability, because product quality depends on it—and regulators demand it. More
View more articles
Bio IT World Lead Gen

 
Industry-spotlight

Riffyn’s pioneering cloud system, Riffyn Nexus, delivers 2X faster development cycles and 4X productivity gains to the world’s most advanced scientific R&D organizations. Its process-centric experiment design, data capture, and data analytics overcome the limitations of ELN and LIMS systems. Its adaptive data integration engine delivers results that are always ready for machine learning.
Read more here!

Industry-spotlight
Trends from the Trenches

Bio-IT World’s Trends from the Trenches podcast delivers your insider’s look at the science, technology, and executive trends driving the life sciences through conversations with industry leaders. BioTeam co-founder Stan Gloss brings years of industry experience in science, data, and technology to conversations exploring what is driving data and discovery, and what’s coming next.
Listen today!